Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • receipt Report ID : 332991
  • calendar_today Published On: Jan, 2023
  • file_copy Pages: 165
  • list Pharmaceuticals and Healthcare
Buy @ $3500

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

According to our latest study, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size was valued at USD 1367.7 million in 2022 and is forecast to a readjusted size of USD 14630 million by 2029 with a CAGR of 40.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

By region, North America has the highest market share, reaching 70.66% in 2019.

Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

This report is a detailed and comprehensive analysis for global Duchenne Muscular Dystrophy (DMD) Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029

Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029

Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029

Global Duchenne Muscular Dystrophy (DMD) Therapeutics market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Duchenne Muscular Dystrophy (DMD) Therapeutics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb and Italfarmaco and etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Duchenne Muscular Dystrophy (DMD) Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Exondys

Emflaza

Translarna

Market segment by Application

Hospitals

Clinics

Home Care

Market segment by players, this report covers

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Duchenne Muscular Dystrophy (DMD) Therapeutics, with revenue, gross margin and global market share of Duchenne Muscular Dystrophy (DMD) Therapeutics from 2018 to 2023.

Chapter 3, the Duchenne Muscular Dystrophy (DMD) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Duchenne Muscular Dystrophy (DMD) Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Duchenne Muscular Dystrophy (DMD) Therapeutics.

Chapter 13, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics research findings and conclusion.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Duchenne Muscular Dystrophy (DMD) Therapeutics

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Duchenne Muscular Dystrophy (DMD) Therapeutics by Type

1.3.1 Overview: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029

1.3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type in 2022

1.3.3 Exondys

1.3.4 Emflaza

1.3.5 Translarna

1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application

1.4.1 Overview: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029

1.4.2 Hospitals

1.4.3 Clinics

1.4.4 Home Care

1.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size & Forecast

1.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast by Region

1.6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

1.6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region, (2018-2029)

1.6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)

1.6.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)

1.6.5 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)

1.6.6 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)

1.6.7 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles

2.1 Sarepta Therapeutics

2.1.1 Sarepta Therapeutics Details

2.1.2 Sarepta Therapeutics Major Business

2.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.1.5 Sarepta Therapeutics Recent Developments and Future Plans

2.2 PTC Therapeutics

2.2.1 PTC Therapeutics Details

2.2.2 PTC Therapeutics Major Business

2.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 PTC Therapeutics Recent Developments and Future Plans

2.3 Pfizer

2.3.1 Pfizer Details

2.3.2 Pfizer Major Business

2.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Pfizer Recent Developments and Future Plans

2.4 Bristol-Myers Squibb

2.4.1 Bristol-Myers Squibb Details

2.4.2 Bristol-Myers Squibb Major Business

2.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans

2.5 Italfarmaco

2.5.1 Italfarmaco Details

2.5.2 Italfarmaco Major Business

2.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.5.5 Italfarmaco Recent Developments and Future Plans

2.6 Santhera Pharmaceuticals

2.6.1 Santhera Pharmaceuticals Details

2.6.2 Santhera Pharmaceuticals Major Business

2.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.6.5 Santhera Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Share by Players (2018-2023)

3.2 Market Share Analysis (2022)

3.2.1 Market Share of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Revenue

3.2.2 Top 3 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2022

3.2.3 Top 6 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2022

3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Overall Company Footprint Analysis

3.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Region Footprint

3.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Type Footprint

3.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value and Market Share by Type (2018-2023)

4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2023)

5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Application (2024-2029)

6 North America

6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)

6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)

6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

6.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)

6.3.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

6.3.3 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

6.3.4 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

7 Europe

7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)

7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)

7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

7.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)

7.3.2 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

7.3.3 France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

7.3.5 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

7.3.6 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific

8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)

8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)

8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region

8.3.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2018-2029)

8.3.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

8.3.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

8.3.4 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

8.3.5 India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

8.3.7 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

9 South America

9.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)

9.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)

9.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

9.3.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)

9.3.2 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

9.3.3 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa

10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

10.3.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)

10.3.2 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

10.3.4 UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics

11.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers

11.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints

11.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

11.5 Influence of COVID-19 and Russia-Ukraine War

11.5.1 Influence of COVID-19

11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

12.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Chain

12.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Upstream Analysis

12.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Midstream Analysis

12.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List of Tables

Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 5. Sarepta Therapeutics Company Information, Head Office, and Major Competitors

Table 6. Sarepta Therapeutics Major Business

Table 7. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 8. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 9. Sarepta Therapeutics Recent Developments and Future Plans

Table 10. PTC Therapeutics Company Information, Head Office, and Major Competitors

Table 11. PTC Therapeutics Major Business

Table 12. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 13. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 14. PTC Therapeutics Recent Developments and Future Plans

Table 15. Pfizer Company Information, Head Office, and Major Competitors

Table 16. Pfizer Major Business

Table 17. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 18. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 19. Pfizer Recent Developments and Future Plans

Table 20. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors

Table 21. Bristol-Myers Squibb Major Business

Table 22. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 23. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 24. Bristol-Myers Squibb Recent Developments and Future Plans

Table 25. Italfarmaco Company Information, Head Office, and Major Competitors

Table 26. Italfarmaco Major Business

Table 27. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 28. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 29. Italfarmaco Recent Developments and Future Plans

Table 30. Santhera Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 31. Santhera Pharmaceuticals Major Business

Table 32. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 33. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 34. Santhera Pharmaceuticals Recent Developments and Future Plans

Table 35. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) by Players (2018-2023)

Table 36. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players (2018-2023)

Table 37. Breakdown of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)

Table 38. Market Position of Players in Duchenne Muscular Dystrophy (DMD) Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022

Table 39. Head Office of Key Duchenne Muscular Dystrophy (DMD) Therapeutics Players

Table 40. Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Type Footprint

Table 41. Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Application Footprint

Table 42. Duchenne Muscular Dystrophy (DMD) Therapeutics New Market Entrants and Barriers to Market Entry

Table 43. Duchenne Muscular Dystrophy (DMD) Therapeutics Mergers, Acquisition, Agreements, and Collaborations

Table 44. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (USD Million) by Type (2018-2023)

Table 45. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Share by Type (2018-2023)

Table 46. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Forecast by Type (2024-2029)

Table 47. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023)

Table 48. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Forecast by Application (2024-2029)

Table 49. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 50. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 51. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 52. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 53. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 54. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 55. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 56. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 57. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 58. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 59. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 60. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 61. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 62. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 63. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 64. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 65. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 66. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 67. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 68. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 69. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 70. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 71. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 72. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 73. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 74. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 75. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 76. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 77. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 78. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 79. Duchenne Muscular Dystrophy (DMD) Therapeutics Raw Material

Table 80. Key Suppliers of Duchenne Muscular Dystrophy (DMD) Therapeutics Raw Materials

List of Figures

Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Picture

Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type in 2022

Figure 4. Exondys

Figure 5. Emflaza

Figure 6. Translarna

Figure 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 8. Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application in 2022

Figure 9. Hospitals Picture

Figure 10. Clinics Picture

Figure 11. Home Care Picture

Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 14. Global Market Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)

Figure 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Region in 2022

Figure 17. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 18. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 19. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 20. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 21. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players in 2022

Figure 23. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 24. Global Top 3 Players Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share in 2022

Figure 25. Global Top 6 Players Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share in 2022

Figure 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Share by Type (2018-2023)

Figure 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Type (2024-2029)

Figure 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Share by Application (2018-2023)

Figure 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Application (2024-2029)

Figure 30. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 31. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 32. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 33. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 34. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 35. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 36. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 37. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 38. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 39. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 40. France Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 41. United Kingdom Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 42. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 43. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 44. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 45. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 46. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 47. China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 48. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 49. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 50. India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 51. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 52. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 53. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 54. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 55. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 56. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 57. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 58. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 59. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 60. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 61. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 62. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 63. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 64. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers

Figure 65. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints

Figure 66. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends

Figure 67. Porters Five Forces Analysis

Figure 68. Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics in 2022

Figure 69. Manufacturing Process Analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics

Figure 70. Duchenne Muscular Dystrophy (DMD) Therapeutics Industrial Chain

Figure 71. Methodology

Figure 72. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz